Earnings ·
Cerus reports Q3 revenue of $64.0M and positive Phase 3 RedeS trial results
CERSCerus Corp
Cerus Corporation reported third-quarter 2026 total revenue of $64.0 million, a 6% increase from the prior year period, driven by product revenue growth of 10% to $57.7 million. The company also announced positive topline results from its Phase 3 RedeS trial for the INTERCEPT Blood System for red blood cells. Cerus reiterated full-year 2026 product revenue guidance of $229 million to $231 million and reported a net loss attributable to the company of $0.6 million, or $0.00 per share. The firm operates in the medical technology sector, developing pathogen reduction systems and blood components for transfusion medicine.